VIVO News and Press, Meridian Bioscience Inc. From 08/06/21

Meridian Bioscience (NASDAQ:VIVO): FQ3 Non-GAAP EPS of $0.22 misses by $0.09; GAAP EPS of $0.27 misses by $0.05. Revenue of $63.51M (-25.1% Y/Y) misses by $9.61M. Press Release For further details see: Meridian Bioscience EPS misses by $0.09, misses on revenue

CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020): • Consolidated net revenues of $63....

CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek ® business from Ots...

Meridian Bioscience ([[VIVO]]) has signed a definitive agreement to acquire the North American BreathTek business from Otsuka America Pharmaceutical for $20M in cash.The transaction is expected to close in Meridian’s fiscal Q4. With this acquisition, Meridian will assume the customer r...

CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek ® business from Otsuka Am...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA And Healthcare Dashboard For July

CINCINNATI, July 14, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter fiscal 2021 financial results Friday, August 6, 2021. Jack Kenny, Chief Executive Officer, and B...

Gainers: Allied Healthcare Products (AHPI) +107%, SCWorx (WORX) +32%, Longboard Pharmaceuticals (LBPH) +18%, Dynatronics (DYNT) +14%, Shineco (TYHT) +13%.Losers: Meridian Bioscience (VIVO) -18%, Aridis Pharmaceuticals (ARDS) -17%, Simulat...

Meridian Bioscience (VIVO) down 2.4% premarket after providing preliminary revenue results for fiscal Q3 2021. The company expects Q3 revenue to be ~$63.5M, below consensus of $73.12M.The Diagnostics segment performance was impacted negatively by supply chain issues w...

CINCINNATI, July 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided preliminary revenue results for its third quarter of fiscal 2021. Preliminary unaudited revenue for the thi...